View all studies | RSV Vaccine

Respiratory Syncytial Virus (RSV) Research Study

Respiratory Syncytial Virus (RSV) is an easily transmittable virus that affects the lungs and airways, with symptoms similar to the flu or COVID-19. Each year, 177,000 adults over 60 are hospitalized due to RSV complications. 

Accellacare is enrolling volunteers into a study evaluating an RSV vaccine. Eligible participants, ages 60+, will receive study-related care and medication at no cost.

Submit to learn more:

When you register your interest with Accellacare, our clinical research specialists will review your information at no cost and connect you with studies you may be eligible for. When we find a match, Accellacare may contact you for further pre-screening or we may share your information with a local site office for them to contact you directly. Your data will be processed as outlined in the Accellacare privacy policy

Data Protection

As the data controller for the Accellacare.us, Accellacare is committed to protecting the information that you provide. Where you give us your consent, we may use your information to: (a) identify appropriate clinical trials for you and to let you know about them; and/or (b) send you invitations to participate in future study opportunities. You can withdraw your consent at any time, but we may continue some limited processing where we have other legal grounds for doing so.

Please enter the security code:



Please note: You may or may not benefit medically from taking part and you are able to opt out at anytime and do not have to give us a reason for doing so. Your primary care physician will be informed about your participation and all medical assessments that will be carried out as part of the study. If during screening any abnormal results are found your primary care physician will also be informed.